<DOC>
	<DOCNO>NCT00801411</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , docetaxel , doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . It yet know chemotherapy regimen effective treat breast cancer . PURPOSE : This randomized phase II trial study cyclophosphamide give together docetaxel see well work compare cyclophosphamide give together doxorubicin treat woman newly diagnose breast cancer remove surgery .</brief_summary>
	<brief_title>Cyclophosphamide Docetaxel Doxorubicin Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate tumor pathological complete response rate neoadjuvant cyclophosphamide combination docetaxel v doxorubicin hydrochloride woman operable clinically node-negative breast cancer normal topoisomerase IIα expression . Secondary - To assess tumor clinical pathological overall response rate patient treat regimen . - To assess safety toxicity regimen . - To assess disease-free survival overall survival patient . - To assess efficacy short-course ( 3 day ) filgrastim ( G-CSF ) primary secondary prophylaxis febrile neutropenia patient receive docetaxel cyclophosphamide . OUTLINE : This multicenter study . Patients stratify accord hormone receptor status ( estrogen receptor [ ER ] - progesterone receptor [ PR ] -positive v ER- PR-negative ) T stage ( T2 v T3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cyclophosphamide IV docetaxel IV 1 hour day 1 . - Arm II : Patients receive cyclophosphamide IV doxorubicin hydrochloride IV day 1 . In arm , treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion neoadjuvant chemotherapy , patient undergo surgery . Tumor specimen obtain prior neoadjuvant chemotherapy analyze topoisomerase IIα gene protein expression IHC FISH . Tissue sample also collect surgery future study . After completion study therapy , patient follow every 3 month 2 year , every 6 month 3 year , annually 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Newly diagnose disease Operable disease Must clinical T2 ( &gt; 2cm ) T3 ( &gt; 5 cm ) primary tumor clinical lymph node involvement ( N0 ) No clinical T4 lesion ( e.g. , peau d'orange , skin ulceration , satellite nodule , inflammatory breast cancer ) No evidence metastatic disease Known hormone receptor status PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status ( PS ) 02 ( Karnofsky PS 60100 % ) Life expectancy &gt; 10 year Leukocytes ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal creatinine clearance ≥ 40 mL/min Normal cardiac ejection fraction , define ≥ 50 % MUGA scan 2DECHO Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biologic composition docetaxel agent use study No history preexist peripheral neuropathy No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement No prior malignancy except curatively treat basal cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No concurrent investigational commercial agent therapy intent treat patient 's malignancy No concurrent chemotherapy , immunotherapy , hormonal cancer therapy , surgery cancer , experimental medication No concurrent combination antiretroviral therapy HIVpositive patient No concurrent antitumor therapy</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage II breast cancer</keyword>
</DOC>